BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26121214)

  • 1. Impaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model.
    Mairhofer DG; Ortner D; Tripp CH; Schaffenrath S; Fleming V; Heger L; Komenda K; Reider D; Dudziak D; Chen S; Becker JC; Flacher V; Stoitzner P
    J Invest Dermatol; 2015 Nov; 135(11):2785-2793. PubMed ID: 26121214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma.
    Alb M; Sie C; Adam C; Chen S; Becker JC; Schrama D
    Cancer Immunol Immunother; 2012 Dec; 61(12):2239-49. PubMed ID: 22674057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.
    Jeanbart L; Kourtis IC; van der Vlies AJ; Swartz MA; Hubbell JA
    Cancer Immunol Immunother; 2015 Aug; 64(8):1033-46. PubMed ID: 25982370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD204 suppresses large heat shock protein-facilitated priming of tumor antigen gp100-specific T cells and chaperone vaccine activity against mouse melanoma.
    Qian J; Yi H; Guo C; Yu X; Zuo D; Chen X; Kane JM; Repasky EA; Subjeck JR; Wang XY
    J Immunol; 2011 Sep; 187(6):2905-14. PubMed ID: 21832164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.
    Schlecker E; Stojanovic A; Eisen C; Quack C; Falk CS; Umansky V; Cerwenka A
    J Immunol; 2012 Dec; 189(12):5602-11. PubMed ID: 23152559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence.
    Jensen SM; Twitty CG; Maston LD; Antony PA; Lim M; Hu HM; Petrausch U; Restifo NP; Fox BA
    J Immunol; 2012 Jul; 189(2):767-76. PubMed ID: 22723522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.
    Walker EB; Miller W; Haley D; Floyd K; Curti B; Urba WJ
    Clin Cancer Res; 2009 Apr; 15(7):2541-51. PubMed ID: 19318471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.
    Kodumudi KN; Weber A; Sarnaik AA; Pilon-Thomas S
    J Immunol; 2012 Dec; 189(11):5147-54. PubMed ID: 23100512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.
    Meyer C; Sevko A; Ramacher M; Bazhin AV; Falk CS; Osen W; Borrello I; Kato M; Schadendorf D; Baniyash M; Umansky V
    Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17111-6. PubMed ID: 21969559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
    Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic DNA vaccine targeting Foxp3
    Namdar A; Mirzaei R; Memarnejadian A; Boghosian R; Samadi M; Mirzaei HR; Farajifard H; Zavar M; Azadmanesh K; Elahi S; Noorbakhsh F; Rezaei A; Hadjati J
    Cancer Immunol Immunother; 2018 Mar; 67(3):367-379. PubMed ID: 29124314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Artificial Antigen-Presenting Cell Delivering 11 Immune Molecules Expands Tumor Antigen-Specific CTLs in
    Zhang L; Song S; Jin X; Wan X; Shahzad KA; Pei W; Zhao C; Shen C
    Cancer Immunol Res; 2019 Jul; 7(7):1188-1201. PubMed ID: 31113806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
    Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
    Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
    Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
    Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8(+) T-cell Response and Protects Mice from Melanoma.
    Qiu Z; Huang H; Grenier JM; Perez OA; Smilowitz HM; Adler B; Khanna KM
    Cancer Immunol Res; 2015 May; 3(5):536-46. PubMed ID: 25633711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
    Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
    Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
    Antony PA; Piccirillo CA; Akpinarli A; Finkelstein SE; Speiss PJ; Surman DR; Palmer DC; Chan CC; Klebanoff CA; Overwijk WW; Rosenberg SA; Restifo NP
    J Immunol; 2005 Mar; 174(5):2591-601. PubMed ID: 15728465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.
    Byrne KT; Zhang P; Steinberg SM; Turk MJ
    J Immunol; 2014 Feb; 192(4):1433-9. PubMed ID: 24403535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immune response to melanoma is limited by thymic selection of self-antigens.
    Träger U; Sierro S; Djordjevic G; Bouzo B; Khandwala S; Meloni A; Mortensen M; Simon AK
    PLoS One; 2012; 7(4):e35005. PubMed ID: 22506061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
    Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
    Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.